[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646922":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":12,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":12,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":12,"enrollmentInfo":61,"targetDuration":12,"studyType":64,"phases":65,"briefSummary":68,"conditions":69,"keywords":12,"overallStatus":34,"whyStopped":12,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Beni-Suef University","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","NO_INTERVENTION","Patients will receive standard of care (SoC) regimen only. The SoC included dietary sodium restriction, treatment with diuretics \\[combination of a loop diuretic (furosemide 40-160 mg\u002Fday or torsemide 5-20 mg\u002Fday) and a distal-acting diuretic (spironolactone 50-400 mg\u002Fday)\\] and large volume paracentesis as needed.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Group B","EXPERIMENTAL","Patients will receive dapagliflozin in addition to standard of care regimen. Based on the pharmacokinetic data of dapagliflozin; Patient with Child Pugh score A and B will receive 10mg\u002Fday and patients with Child Pugh score C will receive 5 mg\u002Fday.",[18],"Drug: Dapagliflozin",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Dapagliflozin","Dapagliflozin is sodium glucose cotransporter type 2 inhibitors (SGLT-2i) primary an antidiabetic drug but now used in chronic heart failure and chronic kidney disease.",[14],[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Raghda Roshdy","CONTACT","+0282-2162135","Raghda.hussien@pharm.bsu.edu.eg",[32],{"facility":33,"status":34,"city":35,"state":12,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Haram Hospital","RECRUITING","Giza","12556","Egypt","EG",{"type":40,"coordinates":41},"Point",[42,43],31.20861,30.00944,{"lat":43,"lon":42},[46],{"name":47,"role":28,"phone":12,"phoneExt":12,"email":48},"asia said","asia_said@yahoo.com",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Asia Said Toukhy","Assistant lecturer in clinical pharmacy","100646922","phase-2-exploring-the-potential-benefits-of-using-dapagliflozin-in-cirrhotic-chronic-liver-disease-patients--a-randomized-controlled-trial-100646922",false,"NCT07684326","\"Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial\"","Inclusion Criteria:\n\n* Adult patients 18 years of age and older with a diagnosis of liver cirrhosis with any degree of ascites that led to previous or recent hospital admission (determined by clinical findings and imaging) will be included in the study.\n\nExclusion Criteria:\n\n1. Child Pugh score ≥ 12 or MELD score \\> 25.\n2. Previous history of hypoglycemia or has a previous history of DKA.\n3. Blood pressure less than 90\u002F60 or need dose of midodrine \\>15 mg\u002Fday.\n4. Previous history of recurrent urinary tract infections (more than 2 infections in the last 6 months) or anatomic urologic defects that predispose to urinary tract infection.\n5. Pregnant or lactating female patients.\n6. Hypersensitivity to dapagliflozin.\n7. eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n8. Had hepatocellular carcinoma or any malignancy.\n9. Serum sodium level \\\u003C 125 mg\u002Fdl.\n10. Portal vein thrombosis.","ALL","18 Years",{"count":62,"type":63},52,"ESTIMATED","INTERVENTIONAL",[66,67],"PHASE2","PHASE3","This study aims to evaluate beneficial effects of using dapagliflozin in cirrhotic chronic liver disease patients. We hypnotized that the use of dapagliflozin will be associated with fewer need for large volume paracentesis hence better control of ascites, fewer need for ICU admissions, improvement of patient quality of life, better healthcare cost saving and reduced mortality rate.",[70],"Ascites Hepatic","2026-06-29",{"date":73,"type":74},"2026-07-06","ACTUAL",{"date":76,"type":63},"2026-07",{"date":78,"type":63},"2027-09",{"name":5,"class":6},1]